#ALLR

Allarity Therapeutics Issues 2025 End of Year CEO Letter to Shareholders TARPON SPRINGS, Fla., December 31, 2025 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—today issued the following letter to

2 months ago

#ALLR Allarity Therapeutics Issues 2025 End of Year CEO Letter to Shareholders

www.stocktitan.net/news/ALLR/allarity-thera...

0 0 0 0

Allarity Therapeutics Provides Third Quarter 2025 Financial Results and Provides Business Updates Allarity Therapeutics (NASDAQ: ALLR) reported Q3 2025 results and operational updates on November 14, 2025. Key clinical progress includes FDA Fast Track designation for stenoparib in advanced ovarian cancer and Phase 2 data showing median overall survival now exceeding 25 months. The company signed a commercial license for selected DRP® breast cancer algorithms and maintains an IBRI research collaboration to study stenoparib’s dual PARP/WNT mechanism. Financially, Allarity ended Q3 with $16.9 million cash (down $0.9M QoQ) and a reported net loss of $2.8 million. The company expects a VA-funded SCLC combination trial to open by year-end 2025 and projects a financial runway through December 2026.

4 months ago

#ALLR Allarity Therapeutics Provides Third Quarter 2025 Financial Results and Provides Business Updates

www.stocktitan.net/news/ALLR/allarity-thera...

0 0 0 0

Allarity Therapeutics Presents New Phase 2 Clinical Data for Stenoparib/2X-121 Showing Landmark Median Overall Survival Has Now Surpassed 25 Months - Kaplan-Meier analyses show for the first time that median Overall Survival exceeds 25 months for Platinum Resistant and Refractory Ovarian Cancer Patients receiving stenoparib/2X-121 twice daily - Two patients continue on therapy now more than 24 months - Clinical Benefit Evident in patients with

5 months ago

#ALLR Allarity Therapeutics Presents New Phase 2 Clinical Data for Stenoparib/2X-121 Showing Landmark Median Overall Survival Has Now Surpassed 25 Months

www.stocktitan.net/news/ALLR/allarity-thera...

0 0 0 0

6 months ago

🚀 Exciting times for #ALLR! Trading at $1.55 with bullish momentum and an RSI over 70, this stock is riding high on positive sentiment from its FDA Fast Track for Stenoparib. Targeting $1.80-$2.00, but watch for volatility. 📈 #FeetrAI #StockMarket #BiotechBoom

0 0 0 0

6 months ago

🚀 Exciting times for #ALLR! Trading at $1.55 with bullish momentum and an RSI over 70, thanks to FDA Fast Track news! 📈 Consider entering at $1.52, targeting $1.75 & $2.00. Set a stop loss at $1.40. Stay alert for updates! #FeetrAI #StockMarket #BiotechBoom

0 0 0 0

6 months ago

🚀 Exciting times for #ALLR! With FDA Fast Track for Stenoparib, investor enthusiasm is soaring. Bullish signals abound, but watch for short-term pullbacks. Entry at $1.58, targets at $1.70 & $1.85. Stop loss: $1.45. Cautious optimism as momentum builds! 📈 #FeetrAI

0 0 0 0

6 months ago

🚀 Exciting times for #ALLR! With FDA Fast Track boosting sentiment, Allarity Therapeutics is on a bullish run. RSI hints at overbought, but MACD shows strong momentum. Entry at $1.55, aiming for $1.80 & $2.00. Stop loss at $1.40. Stay tuned for updates! 📈 #FeetrAI

0 0 0 0

6 months ago

🚀 Exciting times for #ALLR! With FDA approval for a cancer treatment, this stock is set for potential volatility. Watch for a breakout if it opens near $0.50, targeting $0.70 & $0.90. Stay alert for clinical updates and market shifts. 📈 #Biotech #Stocks #FeetrAI

0 0 0 0

6 months ago

🚀 Exciting times for #ALLR! With optimism around clinical trials and FDA fast track approval, this speculative stock is buzzing. Consider a cautious long position at $2.50, targeting $3.00 & $3.50. Stay alert to market trends and news. 📈 #Biotech #InvestSmart

0 0 0 0

6 months ago

🚀 Exciting times for #ALLR! With a solid cash position and FDA fast track approval, potential growth is on the horizon. Consider a long entry at $0.90 with targets at $1.10 & $1.30. Stay cautious with a stop loss at $0.80. Keep an eye on market trends! 📈 #FeetrAI

0 0 0 0

Market Wire News

@marketwirenews.com

6 months ago

JUST IN: ( NASDAQ: #ALLR ) US Companies Moving the Markets, Evening edition <br>Tue, Aug 26, 2025 as of 4:00 pm ET

0 0 0 0

Market Wire News

@marketwirenews.com

6 months ago

Just In: ( NASDAQ: #ALLR ) Power Hour Playbook: Biotech Breakouts, Energy Movers & Niche Innovators to Watch Into the Close

0 0 0 0

6 months ago

🚀 Exciting times for #ALLR! Trading volume is soaring, and the stock's bullish momentum is undeniable, jumping from $0.99 to $2.02! 📈 Consider a long position with an entry at $1.90, targeting $2.20 & $2.50. Manage risk with a stop loss at $1.70. #FeetrAI #StockWatch

0 0 0 0

FDA Fast-Tracks Promising Ovarian Cancer Drug: Allarity's Stenoparib Shows 22-Month Patient Benefits FDA grants Fast Track designation to Allarity's stenoparib for advanced ovarian cancer. Phase 2 trial ongoing with patients showing durable benefits up to 22 months. First patient enrolled June 2025.

6 months ago

#ALLR Allarity Therapeutics Granted FDA Fast Track Designation for Stenoparib for the Treatment of Advanced Ovarian Cancer

www.stocktitan.net/news/ALLR/allarity-thera...

0 0 0 0

Allarity Therapeutics Provides Second Quarter 2025 Update, Highlighting Clinical Progress, IP Expansion, and New Partnerships Allarity Therapeutics (NASDAQ: ALLR) reported significant progress in Q2 2025, highlighted by the initiation of enrollment in their Phase 2 ovarian cancer trial for stenoparib, their dual PARP and WNT pathway inhibitor. The company secured an Australian patent for the Stenoparib DRP® companion diagnostic and established a new service contract with an EU biotech for their medical laboratory.Financial highlights include a cash position of $17.8 million, implementation of a $2.6 million share repurchase program, and a $2 million reduction in accounts payable. Q2 2025 saw R&D expenses of $2.3 million (up from $1.06M in Q2 2024) and G&A expenses of $1.8 million (down from $2.3M). The company reported a net loss of $2.3 million for Q2 2025.Notable appointments include Jesper Høiland to the Board of Directors and Jeffrey S. Ervin as CFO, strengthening the company's leadership team.

7 months ago

#ALLR Allarity Therapeutics Provides Second Quarter 2025 Update, Highlighting Clinical Progress, IP Expansion, and New Partnerships

www.stocktitan.net/news/ALLR/allarity-thera...

0 0 0 0

Major Breast Cancer Breakthrough: Allarity Therapeutics Expands Precision Medicine Platform with New Global License Deal European biotech licenses Allarity's DRP® platform for breast cancer precision medicine. Includes lab services agreement and purchase commitments. See partnership details.

8 months ago

#ALLR Allarity Therapeutics Announces New Licensing and Laboratory Services Agreement to Expand DRP® Platform Utilization

www.stocktitan.net/news/ALLR/allarity-thera...

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

8 months ago

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with improving money flow, Mon Jul 7th - #ZVRA #ZJK #XHG #VIGL #TRS #MDIA #LNSR #KRMD #BTCS #ALLR #OCFT #MUX #MED #AMPX - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0

Allarity Expands Global Patent Portfolio: Key Australian Approval for Cancer Companion Diagnostic Australian patent strengthens Allarity's global IP portfolio for cancer diagnostic technology. Company now holds 19 patents across major markets. Learn expansion details.

8 months ago

#ALLR Allarity Therapeutics Receives Australian Patent Acceptance Notice for Stenoparib DRP® Companion Diagnostic

www.stocktitan.net/news/ALLR/allarity-thera...

0 0 0 0

Allarity Therapeutics Announces Dosing of Second Patient in New Phase 2 Trial of Stenoparib in Advanced Ovarian Cancer Allarity Therapeutics (NASDAQ: ALLR) has announced the dosing of the second patient in its new Phase 2 clinical trial of stenoparib, a dual PARP and WNT pathway inhibitor, for treating advanced, recurrent, platinum-resistant or platinum-ineligible ovarian cancer.The trial builds upon previous Phase 2 data that showed durable clinical benefit and favorable tolerability with twice-daily dosing. The study aims to evaluate stenoparib as a potential novel, targeted treatment option for patients with limited alternatives. Additionally, the trial will advance Allarity's proprietary Drug Response Predictor (DRP®) companion diagnostic and further study stenoparib's unique WNT-modulating mechanism of action.

8 months ago

#ALLR Allarity Therapeutics Announces Dosing of Second Patient in New Phase 2 Trial of Stenoparib in Advanced Ovarian Cancer

www.stocktitan.net/news/ALLR/allarity-thera...

0 0 0 0

Allarity Therapeutics Announces First Patient Enrolled in New Phase 2 Clinical Trial Protocol of Stenoparib in Advanced Ovarian Cancer Allarity Therapeutics (NASDAQ: ALLR) has enrolled the first patient in a new Phase 2 clinical trial of stenoparib for advanced, platinum-resistant or platinum-ineligible ovarian cancer. The trial builds on promising data from an ongoing Phase 2 study where patients receiving twice-daily stenoparib showed durable clinical benefit and good tolerability, with two patients continuing treatment after 20+ months. The new protocol focuses on evaluating stenoparib as a potentially safer alternative to chemotherapy, incorporating the drug-specific DRP companion diagnostic. The study will explore optimal dosing aligned with FDA's Project Optimus initiative and investigate stenoparib's unique WNT pathway modulation. Significant clinical data is expected by late summer 2026, with plans to pursue expedited regulatory pathways for both stenoparib and its companion diagnostic.

9 months ago

#ALLR Allarity Therapeutics Announces First Patient Enrolled in New Phase 2 Clinical Trial Protocol of Stenoparib in Advanced Ovarian Cancer

www.stocktitan.net/news/ALLR/allarity-thera...

0 0 0 0

Allarity Therapeutics Announces Participation in Pharma Partnering Summit US Allarity Therapeutics (NASDAQ: ALLR) has announced its participation in the upcoming Pharma Partnering Summit US, scheduled for May 14-15 in San Diego. CEO Thomas Jensen will present a company overview highlighting their key assets: stenoparib, a Phase 2 dual PARP and WNT pathway inhibitor, and their DRP® companion diagnostic platform. The event serves as a business development and licensing conference for biotech and pharmaceutical executives. Jensen will be available for one-on-one meetings with registered attendees during the summit.

10 months ago

#ALLR Allarity Therapeutics Announces Participation in Pharma Partnering Summit US

www.stocktitan.net/news/ALLR/allarity-thera...

0 0 0 0

Allarity Therapeutics Provides First Quarter 2025 Update, Highlighting Continued Stenoparib Benefit and Upcoming Trial Enrollment Allarity Therapeutics (NASDAQ: ALLR) reported its Q1 2025 financial results and operational updates. The company's lead drug stenoparib continues to show promising results in ovarian cancer treatment, with two patients maintaining treatment benefits for over 19 months. Key financial highlights include a cash balance of $27.7 million, reduced quarterly net loss of $2.7 million (vs $3.8 million in Q1 2024), and lower R&D and G&A expenses. The company has fully utilized its ATM offering and initiated a $5 million share repurchase program, with approximately 2 million shares already repurchased. Upcoming milestones include new trial enrollments for ovarian cancer and small cell lung cancer in combination with temozolomide. The company has also resolved previous SEC matters and had a class action lawsuit dismissed.

10 months ago

#ALLR Allarity Therapeutics Provides First Quarter 2025 Update, Highlighting Continued Stenoparib Benefit and Upcoming Trial Enrollment

www.stocktitan.net/news/ALLR/allarity-thera...

0 0 0 0

Breakthrough: New AI Technology Successfully Predicts Multiple Myeloma Treatment Response with 53-Gene Signature First-ever antibody therapy predictor shows promising results in KYDAR trial. Advanced gene expression analysis reveals 53-gene signature for treatment success. Learn more.

10 months ago

#ALLR Allarity Therapeutics Presents Novel Drug Response Predictor—DRP®—for Daratumumab in Multiple Myeloma at AACR 2025

www.stocktitan.net/news/ALLR/allarity-thera...

1 0 0 0

Allarity's Cancer Drug Shows 17-Month Benefit as Cash Runway Extends to 2027 Strong $20.9M cash position funds operations through 2027. Stenoparib shows promising 17-month benefits in ovarian cancer. Two Phase 2 trials launching in 2025. Full analysis inside.

11 months ago

#ALLR Allarity Therapeutics Reports Full Year 2024 Financial Results and Provides a Business Update

www.stocktitan.net/news/ALLR/allarity-thera...

0 0 0 0

Allarity Takes Bold Action Against Market Manipulation: Launches High-Tech Trading Investigation Advanced DRIL-Down technology deployed to investigate trading irregularities. Company ready to pursue legal action against market manipulation. Full analysis inside.

11 months ago

#ALLR Allarity Therapeutics Launches Comprehensive Effort to Combat Potential Illegal Naked Short Selling of Its Shares

www.stocktitan.net/news/ALLR/allarity-thera...

0 0 0 0